charged multivesicular body protein 1B2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CHMP1B2P profile across patient tissues and cancer cell-line models. CHMP1B2P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CHMP1B2P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CHMP1B2P RNA expression shows 13,719 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where CHMP1B2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHMP1B2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHMP1B2P survival associations across molecular data types. CHMP1B2P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHMP1B2P RNA expression–survival associations across cancer types. High CHMP1B2P expression shows unfavorable associations in LIHC, COAD and OV, but favorable associations in HNSC, MESO and TGCT. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CHMP1B2P RNA expression.
This table summarizes CHMP1B2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CHMP1B2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHMP1B2P shows lower tumor expression in KIRC, KICH, THCA, READ and KIRP and higher tumor expression in STAD. The KIRC box plot shows higher CHMP1B2P RNA expression in normal versus tumor tissue (log2 FC = −0.624, t-test p < 0.001).
This table shows molecular features associated with CHMP1B2P in patient tissues and cancer cell lines. In patient samples, CHMP1B2P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
